Analysts Offer Predictions for Celsion Corp.’s FY2016 Earnings (CLSN)
Celsion Corp. (NASDAQ:CLSN) – Analysts at Cantor Fitzgerald issued their FY2016 earnings per share (EPS) estimates for shares of Celsion Corp. in a research note issued to investors on Tuesday. Cantor Fitzgerald analyst M. Goldstein expects that the brokerage will earn ($0.90) per share for the year.
Several other analysts have also recently commented on the company. Maxim Group reissued a “buy” rating and issued a $4.00 price target on shares of Celsion Corp. in a report on Thursday, September 15th. HC Wainwright reissued a “buy” rating and issued a $3.00 price target on shares of Celsion Corp. in a report on Tuesday, July 12th.
Celsion Corp. (NASDAQ:CLSN) opened at 1.20 on Thursday. Celsion Corp. has a 1-year low of $1.04 and a 1-year high of $2.31. The firm’s market cap is $30.97 million. The firm’s 50-day moving average price is $1.24 and its 200-day moving average price is $1.35.
Celsion Corp. (NASDAQ:CLSN) last released its quarterly earnings data on Monday, August 15th. The company reported ($0.19) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.21) by $0.02. Celsion Corp. had a negative return on equity of 103.07% and a negative net margin of 3,966.14%.
A hedge fund recently bought a new stake in Celsion Corp. stock. Seizert Capital Partners LLC acquired a new stake in shares of Celsion Corp. (NASDAQ:CLSN) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 120,022 shares of the company’s stock, valued at approximately $152,000. Seizert Capital Partners LLC owned approximately 0.51% of Celsion Corp. as of its most recent SEC filing. 15.19% of the stock is owned by institutional investors and hedge funds.
About Celsion Corp.
Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).
Receive News & Stock Ratings for Celsion Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion Corp. and related stocks with our FREE daily email newsletter.